6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
were	VBD	were	were	were	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
gastritis	JJ	gastritis	gastritis	gastriti	Y	B-AdverseReaction
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Boehringer	NNP	boehringer	boehringer	boehring	N	O
Ingelheim	NNP	ingelheim	ingelheim	ingelheim	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
(	(	(	(	(	N	O
800	CD	800	800	800	N	O
)	)	)	)	)	N	O
542	CD	542	542	542	N	O
-	:	-	-	-	N	O
6257	CD	6257	6257	6257	N	O
or	CC	or	or	or	N	O
(	(	(	(	(	N	O
800	CD	800	800	800	N	O
)	)	)	)	)	N	O
459	CD	459	459	459	N	O
-	:	-	-	-	N	O
9906	CD	9906	9906	9906	N	O
TTY	NNP	tty	tty	tti	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
and	CC	and	and	and	N	O
Systemic	NNP	systemic	systemic	system	N	O
Embolism	NNP	embolism	embolism	embol	Y	O
in	IN	in	in	in	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
valvular	JJ	valvular	valvular	valvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NN	fibrillation	fibrillation	fibril	Y	O

The	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
LY	NNP	ly	ly	ly	N	O
(	(	(	(	(	N	O
Randomized	NNP	randomized	randomized	random	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
Anticoagulant	NNP	anticoagulant	anticoagulant	anticoagul	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
study	NN	study	study	studi	N	O
provided	VBD	provided	provided	provid	N	O
safety	NN	safety	safety	safeti	N	O
information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
and	CC	and	and	and	N	O
warfarin	JJ	warfarin	warfarin	warfarin	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
numbers	NNS	numbers	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
their	PRP$	their	their	their	N	O
exposures	NNS	exposures	exposure	exposur	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Limited	JJ	limited	limited	limit	N	O
information	NN	information	information	inform	N	O
is	VBZ	is	is	is	N	O
presented	VBN	presented	presented	present	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
110	CD	110	110	110	N	O
mg	NN	mg	mg	mg	N	O
dosing	NN	dosing	dosing	dose	N	O
arm	NN	arm	arm	arm	N	O
because	IN	because	because	becaus	N	O
this	DT	this	this	thi	N	O
dose	NN	dose	dose	dose	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Exposure	NNP	exposure	exposure	exposur	N	O
in	IN	in	in	in	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
LY	NN	ly	ly	ly	N	O

PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
110	CD	110	110	110	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
Warfarin	NNP	warfarin	warfarin	warfarin	N	O

Total	JJ	total	total	total	N	O
number	NN	number	number	number	N	O
treated	VBD	treated	treated	treat	N	O
5983	CD	5983	5983	5983	N	O
6059	CD	6059	6059	6059	N	O
5998	CD	5998	5998	5998	N	O

Exposure	NN	exposure	exposure	exposur	N	O

12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
4936	CD	4936	4936	4936	N	O
4939	CD	4939	4939	4939	N	O
5193	CD	5193	5193	5193	N	O

24	CD	24	24	24	N	O
months	NNS	months	month	month	N	O
2387	CD	2387	2387	2387	N	O
2405	CD	2405	2405	2405	N	O
2470	CD	2470	2470	2470	N	O

Mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
(	(	(	(	(	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
20.5	CD	20.5	20.5	20.5	N	O
20.3	CD	20.3	20.3	20.3	N	O
21.3	CD	21.3	21.3	21.3	N	O

Total	JJ	total	total	total	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
242	CD	242	242	242	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
261	CD	261	261	261	N	O
10	CD	10	10	10	N	O
,	,	,	,	,	N	O
659	CD	659	659	659	N	O

Drug	NN	drug	drug	drug	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
LY	NN	ly	ly	ly	N	O

The	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
21%	CD	21%	21%	21%	N	O
for	IN	for	for	for	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
16%	CD	16%	16%	16%	N	O
for	IN	for	for	for	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
were	VBD	were	were	were	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
LY	NNP	ly	ly	ly	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
rate	NN	rate	rate	rate	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
subject	JJ	subject	subject	subject	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	B-Severity
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
of	IN	of	of	of	N	O
2	CD	2	2	2	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
packed	JJ	packed	packed	pack	N	O
red	JJ	red	red	red	N	O
blood	NN	blood	blood	blood	N	O
cells	NNS	cells	cell	cell	N	O
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
a	DT	a	a	a	N	I-AdverseReaction
critical	JJ	critical	critical	critic	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
.	.	.	.	.	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
included	VBD	included	included	includ	N	O
intracerebral	JJ	intracerebral	intracerebral	intracerebr	N	B-AdverseReaction
(	(	(	(	(	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
subarachnoid	JJ	subarachnoid	subarachnoid	subarachnoid	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Adjudicated	NNP	adjudicated	adjudicated	adjud	N	O
Major	NNP	major	major	major	N	B-Severity
Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Treated	NNP	treated	treated	treat	N	O
Patientsa	NNP	patientsa	patientsa	patientsa	N	O

aPatients	NNS	apatients	apatients	apati	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
or	CC	or	or	or	N	O
within	IN	within	within	within	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
stopping	VBG	stopping	stopping	stop	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
within	IN	within	within	within	N	O
each	DT	each	each	each	N	O
subcategory	NN	subcategory	subcategory	subcategori	N	O
were	VBD	were	were	were	N	O
counted	VBN	counted	counted	count	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
contributed	VBN	contributed	contributed	contribut	N	O
events	NNS	events	event	event	N	O
to	TO	to	to	to	N	O
multiple	VB	multiple	multiple	multipl	N	O
subcategories	NNS	subcategories	subcategories	subcategori	N	O
.	.	.	.	.	N	O

bAnnual	JJ	bannual	bannual	bannual	N	O
event	NN	event	event	event	N	O
rate	NN	rate	rate	rate	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
pt	JJ	pt	pt	pt	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
100	CD	100	100	100	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
event	NN	event	event	event	N	O
subject	JJ	subject	subject	subject	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Subject	JJ	subject	subject	subject	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
is	VBZ	is	is	is	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
days	NNS	days	day	day	N	O
from	IN	from	from	from	N	O
first	JJ	first	first	first	N	O
drug	NN	drug	drug	drug	N	O
intake	NN	intake	intake	intak	N	O
to	TO	to	to	to	N	O
event	NN	event	event	event	N	O
date	NN	date	date	date	N	O
,	,	,	,	,	N	O
date	NN	date	date	date	N	O
of	IN	of	of	of	N	O
last	JJ	last	last	last	N	O
drug	NN	drug	drug	drug	N	O
intake	NN	intake	intake	intak	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
death	NN	death	death	death	Y	O
date	NN	date	date	date	N	O
(	(	(	(	(	N	O
whatever	WDT	whatever	whatever	whatev	N	O
occurred	VBD	occurred	occurred	occur	N	O
first	RB	first	first	first	N	O
)	)	)	)	)	N	O
across	IN	across	across	across	N	O
all	DT	all	all	all	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
divided	VBN	divided	divided	divid	N	O
by	IN	by	by	by	N	O
365.25	CD	365.25	365.25	365.25	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
category	NN	category	category	categori	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
event	NN	event	event	event	N	O
was	VBD	was	wa	wa	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

cDefined	VBN	cdefined	cdefined	cdefin	N	O
as	IN	as	a	as	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
of	IN	of	of	of	N	O
2	CD	2	2	2	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
packed	JJ	packed	packed	pack	N	O
red	JJ	red	red	red	N	O
blood	NN	blood	blood	blood	N	O
cells	NNS	cells	cell	cell	N	O
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
a	DT	a	a	a	N	I-AdverseReaction
critical	JJ	critical	critical	critic	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
.	.	.	.	.	N	O

dIntracranial	JJ	dintracranial	dintracranial	dintracrani	N	B-AdverseReaction
bleed	NN	bleed	bleed	bleed	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
intracerebral	JJ	intracerebral	intracerebral	intracerebr	N	B-AdverseReaction
(	(	(	(	(	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
subarachnoid	JJ	subarachnoid	subarachnoid	subarachnoid	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
subdural	JJ	subdural	subdural	subdur	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
.	.	.	.	.	N	O

eOn	SYM	eon	eon	eon	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
analysis	NN	analysis	analysis	analysi	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
ITT	NNP	itt	itt	itt	N	O
analysis	NN	analysis	analysis	analysi	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Section	NNP	section	section	section	N	O
14	CD	14	14	14	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNPS	studies	study	studi	N	O
.	.	.	.	.	N	O

fFatal	JJ	ffatal	ffatal	ffatal	N	B-AdverseReaction
bleed	NN	bleed	bleed	bleed	N	B-AdverseReaction
:	:	:	:	:	N	O
Adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
major	JJ	major	major	major	N	B-Severity
bleed	NN	bleed	bleed	bleed	N	B-AdverseReaction
as	IN	as	a	as	N	O
defined	VBN	defined	defined	defin	N	O
above	IN	above	above	abov	N	O
with	IN	with	with	with	N	O
investigator	NN	investigator	investigator	investig	N	O
reported	VBD	reported	reported	report	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
and	CC	and	and	and	N	O
adjudicated	VBD	adjudicated	adjudicated	adjud	N	O
death	NN	death	death	death	Y	B-AdverseReaction
with	IN	with	with	with	N	O
primary	JJ	primary	primary	primari	N	O
cause	NN	cause	cause	caus	N	O
from	IN	from	from	from	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

gNon	SYM	gnon	gnon	gnon	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleed	NN	bleed	bleed	bleed	N	I-AdverseReaction
:	:	:	:	:	N	O
Adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
major	JJ	major	major	major	N	B-Severity
bleed	NN	bleed	bleed	bleed	N	B-AdverseReaction
as	IN	as	a	as	N	O
defined	VBN	defined	defined	defin	N	O
above	IN	above	above	abov	N	O
and	CC	and	and	and	N	O
adjudicated	VBD	adjudicated	adjudicated	adjud	N	O
death	NN	death	death	death	Y	B-AdverseReaction
with	IN	with	with	with	N	O
primary	JJ	primary	primary	primari	N	O
cause	NN	cause	cause	caus	N	O
from	IN	from	from	from	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
but	CC	but	but	but	N	O
without	IN	without	without	without	N	B-Negation
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
bleed	NN	bleed	bleed	bleed	N	I-AdverseReaction
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
investigator	NN	investigator	investigator	investig	N	O
's	POS	's	's	's	N	O
clinical	JJ	clinical	clinical	clinic	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

Event	NN	event	event	event	N	O

PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mgN	NN	mgn	mgn	mgn	N	O
6059	CD	6059	6059	6059	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
year	NN	year	year	year	N	O
b	NN	b	b	b	N	O
)	)	)	)	)	N	O
WarfarinN	IN	warfarinn	warfarinn	warfarinn	N	O
5998	CD	5998	5998	5998	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
year	NN	year	year	year	N	O
b	NN	b	b	b	N	O
)	)	)	)	)	N	O
PRADAXA	VBZ	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mgvs	NN	mgvs	mgvs	mgv	N	O
.	.	.	.	.	N	O

WarfarinHR	NNP	warfarinhr	warfarinhr	warfarinhr	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
CI	NNP	ci	ci	ci	N	O
)	)	)	)	)	N	O

Major	JJ	major	major	major	N	B-Severity
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
c	NN	c	c	c	N	O
350	CD	350	350	350	N	O
(	(	(	(	(	N	O
3.47	CD	3.47	3.47	3.47	N	O
)	)	)	)	)	N	O
374	CD	374	374	374	N	O
(	(	(	(	(	N	O
3.58	CD	3.58	3.58	3.58	N	O
)	)	)	)	)	N	O
0.97	CD	0.97	0.97	0.97	N	O
(	(	(	(	(	N	O
0.84	CD	0.84	0.84	0.84	N	O
,	,	,	,	,	N	O
1.12	CD	1.12	1.12	1.12	N	O
)	)	)	)	)	N	O

Intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
Hemorrhage	NNP	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
ICH	NNP	ich	ich	ich	N	B-AdverseReaction
)	)	)	)	)	N	O
d	VBZ	d	d	d	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
0.22	CD	0.22	0.22	0.22	N	O
)	)	)	)	)	N	O
82	CD	82	82	82	N	O
(	(	(	(	(	N	O
0.77	CD	0.77	0.77	0.77	N	O
)	)	)	)	)	N	O
0.29	CD	0.29	0.29	0.29	N	O
(	(	(	(	(	N	O
0.18	CD	0.18	0.18	0.18	N	O
,	,	,	,	,	N	O
0.46	CD	0.46	0.46	0.46	N	O
)	)	)	)	)	N	O

Hemorrhagic	NNP	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
Stroke	NNP	stroke	stroke	stroke	Y	I-AdverseReaction
e	VBZ	e	e	e	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
0.06	CD	0.06	0.06	0.06	N	O
)	)	)	)	)	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
0.37	CD	0.37	0.37	0.37	N	O
)	)	)	)	)	N	O
0.16	CD	0.16	0.16	0.16	N	O
(	(	(	(	(	N	O
0.07	CD	0.07	0.07	0.07	N	O
,	,	,	,	,	N	O
0.37	CD	0.37	0.37	0.37	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
ICH	NNP	ich	ich	ich	N	B-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
0.17	CD	0.17	0.17	0.17	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
0.43	CD	0.43	0.43	0.43	N	O
)	)	)	)	)	N	O
0.38	CD	0.38	0.38	0.38	N	O
(	(	(	(	(	N	O
0.22	CD	0.22	0.22	0.22	N	O
,	,	,	,	,	N	O
0.67	CD	0.67	0.67	0.67	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
162	CD	162	162	162	N	O
(	(	(	(	(	N	O
1.59	CD	1.59	1.59	1.59	N	O
)	)	)	)	)	N	O
111	CD	111	111	111	N	O
(	(	(	(	(	N	O
1.05	CD	1.05	1.05	1.05	N	O
)	)	)	)	)	N	O
1.51	CD	1.51	1.51	1.51	N	O
(	(	(	(	(	N	O
1.19	CD	1.19	1.19	1.19	N	O
,	,	,	,	,	N	O
1.92	CD	1.92	1.92	1.92	N	O
)	)	)	)	)	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
f	NN	f	f	f	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.07	CD	0.07	0.07	0.07	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
0.15	CD	0.15	0.15	0.15	N	O
)	)	)	)	)	N	O
0.45	CD	0.45	0.45	0.45	N	O
(	(	(	(	(	N	O
0.19	CD	0.19	0.19	0.19	N	O
,	,	,	,	,	N	O
1.10	CD	1.10	1.10	1.10	N	O
)	)	)	)	)	N	O

ICH	NNP	ich	ich	ich	N	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.03	CD	0.03	0.03	0.03	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
0.08	CD	0.08	0.08	0.08	N	O
)	)	)	)	)	N	O
0.35	CD	0.35	0.35	0.35	N	O
(	(	(	(	(	N	O
0.09	CD	0.09	0.09	0.09	N	O
,	,	,	,	,	N	O
1.28	CD	1.28	1.28	1.28	N	O
)	)	)	)	)	N	O

Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	O
g	NN	g	g	g	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.04	CD	0.04	0.04	0.04	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.07	CD	0.07	0.07	0.07	N	O
)	)	)	)	)	N	O
0.59	CD	0.59	0.59	0.59	N	O
(	(	(	(	(	N	O
0.17	CD	0.17	0.17	0.17	N	O
,	,	,	,	,	N	O
2.02	CD	2.02	2.02	2.02	N	O
)	)	)	)	)	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
(	(	(	(	(	N	O
6.6%	CD	6.6%	6.6%	6.6%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

4.2%	CD	4.2%	4.2%	4.2%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
major	JJ	major	major	major	N	B-Severity
bleeds	NNS	bleeds	bleeds	bleed	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
across	IN	across	across	across	N	O
major	JJ	major	major	major	N	O
subgroups	NNS	subgroups	subgroup	subgroup	N	O
defined	VBN	defined	defined	defin	N	O
by	IN	by	by	by	N	O
baseline	NN	baseline	baseline	baselin	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Figure	NNP	figure	figure	figur	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
exception	NN	exception	exception	except	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
where	WRB	where	where	where	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
trend	NN	trend	trend	trend	N	O
towards	VBZ	towards	towards	toward	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
on	IN	on	on	on	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
(	(	(	(	(	N	O
hazard	JJ	hazard	hazard	hazard	N	O
ratio	NN	ratio	ratio	ratio	N	O
1.2	CD	1.2	1.2	1.2	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
CI	NN	ci	ci	ci	N	O
:	:	:	:	:	N	O
1.0	CD	1.0	1.0	1.0	N	O
to	TO	to	to	to	N	O
1.5	CD	1.5	1.5	1.5	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Figure	NN	figure	figure	figur	N	O
1	CD	1	1	1	N	O
Adjudicated	NNP	adjudicated	adjudicated	adjud	N	O
Major	NNP	major	major	major	N	B-Severity
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
by	IN	by	by	by	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Characteristics	NNPS	characteristics	characteristic	characterist	N	O
Including	NNP	including	including	includ	N	O
Hemorrhagic	NNP	hemorrhagic	hemorrhagic	hemorrhag	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
figure	NN	figure	figure	figur	N	O
above	IN	above	above	abov	N	O
presents	NNS	presents	present	present	N	O
effects	NNS	effects	effect	effect	N	O
in	IN	in	in	in	N	O
various	JJ	various	various	variou	N	O
subgroups	NNS	subgroups	subgroup	subgroup	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
baseline	JJ	baseline	baseline	baselin	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
were	VBD	were	were	were	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
specified	VBN	specified	specified	specifi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
limits	NNS	limits	limit	limit	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
do	JJ	do	do	do	N	O
not	RB	not	not	not	N	O
take	VB	take	take	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
how	WRB	how	how	how	N	O
many	JJ	many	many	mani	N	O
comparisons	NNS	comparisons	comparison	comparison	N	O
were	VBD	were	were	were	N	O
made	VBN	made	made	made	N	O
,	,	,	,	,	N	O
nor	CC	nor	nor	nor	N	O
do	VBP	do	do	do	N	O
they	PRP	they	they	they	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
particular	JJ	particular	particular	particular	N	O
factor	NN	factor	factor	factor	N	O
after	IN	after	after	after	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Apparent	JJ	apparent	apparent	appar	N	O
homogeneity	NN	homogeneity	homogeneity	homogen	N	O
or	CC	or	or	or	N	O
heterogeneity	NN	heterogeneity	heterogeneity	heterogen	N	O
among	IN	among	among	among	N	O
groups	NNS	groups	group	group	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
over	IN	over	over	over	N	O
-	:	-	-	-	N	O
interpreted	VBN	interpreted	interpreted	interpret	N	O
.	.	.	.	.	N	O

Figure	NN	figure	figure	figur	N	O
1	CD	1	1	1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
35%	CD	35%	35%	35%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

24%	CD	24%	24%	24%	N	O
on	IN	on	on	on	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
were	VBD	were	were	were	N	O
commonly	RB	commonly	commonly	commonli	N	O
dyspepsia	JJ	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
epigastric	JJ	epigastric	epigastric	epigastr	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
gastritis	$	gastritis	gastritis	gastriti	Y	B-AdverseReaction
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
GERD	NNP	gerd	gerd	gerd	Y	B-AdverseReaction
,	,	,	,	,	N	O
esophagitis	NN	esophagitis	esophagitis	esophag	Y	B-AdverseReaction
,	,	,	,	,	N	O
erosive	JJ	erosive	erosive	eros	N	B-AdverseReaction
gastritis	NN	gastritis	gastritis	gastriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
gastritis	NN	gastritis	gastritis	gastriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
erosive	JJ	erosive	erosive	eros	N	I-AdverseReaction
gastritis	NN	gastritis	gastritis	gastriti	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
LY	NNP	ly	ly	ly	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O

and	CC	and	and	and	N	O
Reduction	NNP	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Recurrence	NNP	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
Deep	NNP	deep	deep	deep	N	O
Venous	NNP	venous	venous	venou	N	O
Thrombosis	NNP	thrombosis	thrombosis	thrombosi	Y	O
and	CC	and	and	and	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Embolism	NNP	embolism	embolism	embol	Y	O

PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
4387	CD	4387	4387	4387	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
pivotal	JJ	pivotal	pivotal	pivot	N	O
,	,	,	,	,	N	O
parallel	JJ	parallel	parallel	parallel	N	O
,	,	,	,	,	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
(	(	(	(	(	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
,	,	,	,	,	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
II	NNP	ii	ii	ii	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NN	medy	medy	medi	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
study	NN	study	study	studi	N	O
(	(	(	(	(	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
placebo	VBN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
demographic	JJ	demographic	demographic	demograph	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
4	CD	4	4	4	N	O
pivotal	JJ	pivotal	pivotal	pivot	N	O
studies	NNS	studies	study	studi	N	O
and	CC	and	and	and	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
within	IN	within	within	within	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
60%	CD	60%	60%	60%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
55.1	CD	55.1	55.1	55.1	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
(	(	(	(	(	N	O
87.7%	CD	87.7%	87.7%	87.7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
10.3%	CD	10.3%	10.3%	10.3%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
were	VBD	were	were	were	N	O
black	JJ	black	black	black	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
CrCl	NNP	crcl	crcl	crcl	N	O
of	IN	of	of	of	N	O
105.6	CD	105.6	105.6	105.6	N	O
mL	NNS	ml	ml	ml	N	O
min	NN	min	min	min	N	O
.	.	.	.	.	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
4	CD	4	4	4	N	O
pivotal	JJ	pivotal	pivotal	pivot	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
classified	VBN	classified	classified	classifi	N	O
as	IN	as	a	as	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
if	IN	if	if	if	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
criteria	NNS	criteria	criterion	criteria	N	O
applied	VBN	applied	applied	appli	N	O
:	:	:	:	:	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
,	,	,	,	,	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
a	DT	a	a	a	N	I-AdverseReaction
critical	JJ	critical	critical	critic	N	I-AdverseReaction
area	NN	area	area	area	N	I-AdverseReaction
or	CC	or	or	or	N	O
organ	NN	organ	organ	organ	N	I-AdverseReaction
(	(	(	(	(	N	O
intraocular	JJ	intraocular	intraocular	intraocular	N	I-AdverseReaction
,	,	,	,	,	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	I-AdverseReaction
,	,	,	,	,	N	O
intraspinal	JJ	intraspinal	intraspinal	intraspin	N	I-AdverseReaction
or	CC	or	or	or	N	O
intramuscular	JJ	intramuscular	intramuscular	intramuscular	N	I-AdverseReaction
with	IN	with	with	with	N	O
compartment	JJ	compartment	compartment	compart	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
retroperitoneal	NN	retroperitoneal	retroperitoneal	retroperiton	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
intra	JJ	intra	intra	intra	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
articular	JJ	articular	articular	articular	N	I-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
causing	VBG	causing	causing	caus	N	O
a	DT	a	a	a	N	O
fall	NN	fall	fall	fall	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	JJ	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
level	NN	level	level	level	N	I-AdverseReaction
of	IN	of	of	of	N	O
2.0	CD	2.0	2.0	2.0	N	B-Severity
g	NNS	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
1.24	CD	1.24	1.24	1.24	N	O
mmol	NN	mmol	mmol	mmol	N	O
L	NNP	l	l	l	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
of	IN	of	of	of	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
units	NNS	units	unit	unit	N	O
of	IN	of	of	of	N	O
whole	JJ	whole	whole	whole	N	O
blood	NN	blood	blood	blood	N	O
or	CC	or	or	or	N	O
red	JJ	red	red	red	N	O
cells	NNS	cells	cell	cell	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
and	CC	and	and	and	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
II	NNP	ii	ii	ii	N	O
studies	NNS	studies	study	studi	N	O
compared	VBN	compared	compared	compar	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
warfarin	VB	warfarin	warfarin	warfarin	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
deep	JJ	deep	deep	deep	N	O
vein	NN	vein	vein	vein	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
embolism	NN	embolism	embolism	embol	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
approved	JJ	approved	approved	approv	N	O
parenteral	JJ	parenteral	parenteral	parenter	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
therapy	NN	therapy	therapy	therapi	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
164	CD	164	164	164	N	O
days	NNS	days	day	day	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
oral	JJ	oral	oral	oral	N	O
only	RB	only	only	onli	N	O
treatment	NN	treatment	treatment	treatment	N	O
;	:	;	;	;	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
was	VBD	was	wa	wa	N	O
overlapped	VBN	overlapped	overlapped	overlap	N	O
with	IN	with	with	with	N	O
parenteral	JJ	parenteral	parenteral	parenter	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
and	CC	and	and	and	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
II	NNP	ii	ii	ii	N	O
studies	NNS	studies	study	studi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
full	JJ	full	full	full	N	O
treatment	NN	treatment	treatment	treatment	N	O
including	VBG	including	including	includ	N	O
parenteral	JJ	parenteral	parenteral	parenter	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	O
only	RB	only	only	onli	N	O
treatment	NN	treatment	treatment	treatment	N	O
periods	NNS	periods	period	period	N	O
after	IN	after	after	after	N	O
randomization	NN	randomization	randomization	random	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
and	CC	and	and	and	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
COVER	NNP	cover	cover	cover	N	O
II	NNP	ii	ii	ii	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
MBE	NN	mbe	mbe	mbe	N	B-AdverseReaction
can	MD	can	can	can	N	O
belong	VB	belong	belong	belong	N	O
to	TO	to	to	to	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
criterion	NN	criterion	criterion	criterion	N	O
.	.	.	.	.	N	O

a	DT	a	a	a	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
MBE	NNP	mbe	mbe	mbe	N	B-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
site	NN	site	site	site	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
investigator	NN	investigator	investigator	investig	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
can	MD	can	can	can	N	O
have	VB	have	have	have	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
site	NN	site	site	site	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Confidence	NNP	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O

Patients	NNS	patients	patient	patient	N	O

Major	JJ	major	major	major	N	B-Severity

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

event	NN	event	event	event	N	O

a	DT	a	a	a	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction

sites	NNS	sites	site	site	N	O

for	IN	for	for	for	N	O

MBE	NNP	mbe	mbe	mbe	N	B-AdverseReaction
b	NN	b	b	b	N	O

Clinically	RB	clinically	clinically	clinic	N	O

relevant	NN	relevant	relevant	relev	N	O

non	NN	non	non	non	N	B-Severity

-	:	-	-	-	N	I-Severity

major	JJ	major	major	major	N	I-Severity

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

Any	DT	any	any	ani	N	O

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

The	DT	the	the	the	N	O

rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
full	JJ	full	full	full	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
was	VBD	was	wa	wa	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
(	(	(	(	(	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
on	IN	on	on	on	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NN	medy	medy	medi	N	O
and	CC	and	and	and	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
studies	NNS	studies	study	studi	N	O
provided	VBD	provided	provided	provid	N	O
safety	NN	safety	safety	safeti	N	O
information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
deep	JJ	deep	deep	deep	N	O
vein	NN	vein	vein	vein	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
embolism	NN	embolism	embolism	embol	Y	O
.	.	.	.	.	N	O

RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NNP	medy	medy	medi	N	O
was	VBD	was	wa	wa	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
(	(	(	(	(	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
1430	CD	1430	1430	1430	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
following	VBG	following	following	follow	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
studies	NNS	studies	study	studi	N	O
who	WP	who	who	who	N	O
rolled	VBD	rolled	rolled	roll	N	O
over	RB	over	over	over	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NNP	medy	medy	medi	N	O
study	NN	study	study	studi	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
combined	VBN	combined	combined	combin	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
473	CD	473	473	473	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NNP	medy	medy	medi	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
MBE	NN	mbe	mbe	mbe	N	B-AdverseReaction
can	MD	can	can	can	N	O
belong	VB	belong	belong	belong	N	O
to	TO	to	to	to	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
criterion	NN	criterion	criterion	criterion	N	O
.	.	.	.	.	N	O

a	DT	a	a	a	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
MBE	NNP	mbe	mbe	mbe	N	B-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
site	NN	site	site	site	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
investigator	NN	investigator	investigator	investig	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
can	MD	can	can	can	N	O
have	VB	have	have	have	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
site	NN	site	site	site	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Confidence	NNP	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O

Patients	NNS	patients	patient	patient	N	O

Major	JJ	major	major	major	N	B-Severity

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

event	NN	event	event	event	N	O
a	DT	a	a	a	N	O

Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction

sites	NNS	sites	site	site	N	O

for	IN	for	for	for	N	O

MBE	NNP	mbe	mbe	mbe	N	B-AdverseReaction
b	NN	b	b	b	N	O

Clinically	RB	clinically	clinically	clinic	N	O

relevant	NN	relevant	relevant	relev	N	O

non	NN	non	non	non	N	B-Severity

-	:	-	-	-	N	I-Severity

major	JJ	major	major	major	N	I-Severity

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

Any	DT	any	any	ani	N	O

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O

RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
MEDY	NNP	medy	medy	medi	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
(	(	(	(	(	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
on	IN	on	on	on	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

RE	NN	re	re	re	N	O

-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
684	CD	684	684	684	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
following	VBG	following	following	follow	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
18	CD	18	18	18	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
studies	NNS	studies	study	studi	N	O
who	WP	who	who	who	N	O
rolled	VBD	rolled	rolled	roll	N	O
over	RB	over	over	over	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
study	NN	study	study	studi	N	O
had	VBD	had	had	had	N	O
combined	VBN	combined	combined	combin	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
9	CD	9	9	9	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
165	CD	165	165	165	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
shows	VBZ	shows	show	show	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
Bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

Note	NN	note	note	note	N	O
:	:	:	:	:	N	O
MBE	NN	mbe	mbe	mbe	N	B-AdverseReaction
can	MD	can	can	can	N	O
belong	VB	belong	belong	belong	N	O
to	TO	to	to	to	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
criterion	NN	criterion	criterion	criterion	N	O
.	.	.	.	.	N	O

a	DT	a	a	a	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
MBE	NNP	mbe	mbe	mbe	N	B-AdverseReaction
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	B-AdverseReaction
site	NN	site	site	site	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
investigator	NN	investigator	investigator	investig	N	O
assessment	NN	assessment	assessment	assess	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
can	MD	can	can	can	N	O
have	VB	have	have	have	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
site	NN	site	site	site	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
Confidence	NNP	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O

Patients	NNS	patients	patient	patient	N	O

Major	JJ	major	major	major	N	B-Severity

bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

event	NN	event	event	event	N	O
a	DT	a	a	a	N	O

Clinically	RB	clinically	clinically	clinic	N	O

relevant	NN	relevant	relevant	relev	N	O

non	SYM	non	non	non	N	B-Severity
-	:	-	-	-	N	I-Severity
major	JJ	major	major	major	N	I-Severity
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

Any	DT	any	any	ani	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
SONATE	NN	sonate	sonate	sonat	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
bleeds	NNS	bleeds	bleeds	bleed	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Myocardial	JJ	myocardial	myocardial	myocardi	N	O
Infarction	NNP	infarction	infarction	infarct	Y	O
Events	NNS	events	event	event	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
VTE	NNP	vte	vte	vte	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
[	NNP	[	[	[	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
0.66	CD	0.66	0.66	0.66	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)]	VBP	)]	)]	)]	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
warfarin	JJ	warfarin	warfarin	warfarin	N	O
[	JJ	[	[	[	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
0.17	CD	0.17	0.17	0.17	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)]	VBP	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
similar	JJ	similar	similar	similar	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	B-Severity
-	:	-	-	-	N	I-Severity
fatal	NN	fatal	fatal	fatal	N	I-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
clinical	JJ	clinical	clinical	clinic	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
[	NNP	[	[	[	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.32	CD	0.32	0.32	0.32	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)]	VBP	)]	)]	)]	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
[	NN	[	[	[	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.34	CD	0.34	0.34	0.34	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
)]	VBP	)]	)]	)]	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
four	CD	four	four	four	N	O
pivotal	JJ	pivotal	pivotal	pivot	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
similar	JJ	similar	similar	similar	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
24.7%	CD	24.7%	24.7%	24.7%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

22.7%	CD	22.7%	22.7%	22.7%	N	O
on	IN	on	on	on	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
epigastric	JJ	epigastric	epigastric	epigastr	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
in	IN	in	in	in	N	O
7.5%	CD	7.5%	7.5%	7.5%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

5.5%	CD	5.5%	5.5%	5.5%	N	O
on	IN	on	on	on	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastritis	SYM	gastritis	gastritis	gastriti	Y	B-AdverseReaction
-	:	-	-	-	N	O
like	IN	like	like	like	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
GERD	NNP	gerd	gerd	gerd	Y	B-AdverseReaction
,	,	,	,	,	N	O
esophagitis	NN	esophagitis	esophagitis	esophag	Y	B-AdverseReaction
,	,	,	,	,	N	O
erosive	JJ	erosive	erosive	eros	N	B-AdverseReaction
gastritis	NN	gastritis	gastritis	gastriti	Y	I-AdverseReaction
and	CC	and	and	and	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

1.7%	CD	1.7%	1.7%	1.7%	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
4	CD	4	4	4	N	O
pivotal	JJ	pivotal	pivotal	pivot	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
:	:	:	:	:	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
esophageal	JJ	esophageal	esophageal	esophag	N	B-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	O
EVENTS	NNP	events	event	event	N	O
,	,	,	,	,	N	O
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	O
EVENTS	NNP	events	event	event	N	O
,	,	,	,	,	N	O
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
A	NNP	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
OF	NNP	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	O
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	O
EVENTSPremature	NNP	eventspremature	eventspremature	eventsprematur	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
,	,	,	,	,	N	O
increases	VBZ	increases	increase	increas	N	O
\n\n	VBP	\n\n	\n\n	\n\n	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anticoagulation	NN	anticoagulation	anticoagulation	anticoagul	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
is	VBZ	is	is	is	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
,	,	,	,	,	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	O
EPIDURAL	NNP	epidural	epidural	epidur	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
HEMATOMAEpidural	NNP	hematomaepidural	hematomaepidural	hematomaepidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematomas	NN	hematomas	hematoma	hematoma	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
undergoing	JJ	undergoing	undergoing	undergo	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
term	NN	term	term	term	N	I-AdverseReaction
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
\n\n	JJ	\n\n	\n\n	\n\n	N	I-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
these	DT	these	these	these	N	O
risks	NNS	risks	risk	risk	N	O
when	WRB	when	when	when	N	O
scheduling	VBG	scheduling	scheduling	schedul	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
spinal	JJ	spinal	spinal	spinal	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
procedures	NNS	procedures	procedure	procedur	N	O
.	.	.	.	.	N	O

Factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
epidural	JJ	epidural	epidural	epidur	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
indwelling	VBG	indwelling	indwelling	indwel	N	O
epidural	JJ	epidural	epidural	epidur	N	O
catheters	NNS	catheters	catheter	cathet	N	O
concomitant	VBP	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	IN	that	that	that	N	O
affect	JJ	affect	affect	affect	N	O
hemostasis	NN	hemostasis	hemostasis	hemostasi	Y	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
steroidal	NN	steroidal	steroidal	steroid	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
platelet	JJ	platelet	platelet	platelet	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
\n\n	FW	\n\n	\n\n	\n\n	N	O
other	JJ	other	other	other	N	O
anticoagulants	NNS	anticoagulants	anticoagulant	anticoagul	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
traumatic	JJ	traumatic	traumatic	traumat	N	O
or	CC	or	or	or	N	O
repeated	VBN	repeated	repeated	repeat	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
punctures	NNS	punctures	puncture	punctur	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
spinal	JJ	spinal	spinal	spinal	N	O
deformity	NN	deformity	deformity	deform	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
optimal	JJ	optimal	optimal	optim	N	O
timing	NN	timing	timing	time	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
and	CC	and	and	and	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
procedures	NNS	procedures	procedure	procedur	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
\n\n	VBP	\n\n	\n\n	\n\n	N	O
frequently	RB	frequently	frequently	frequent	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
compromise	NN	compromise	compromise	compromis	N	O
is	VBZ	is	is	is	N	O
noted	VBN	noted	noted	note	N	O
,	,	,	,	,	N	O
urgent	JJ	urgent	urgent	urgent	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
before	IN	before	before	befor	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
intervention	NN	intervention	intervention	intervent	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
anticoagulated	VBD	anticoagulated	anticoagulated	anticoagul	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
anticoagulated	VBN	anticoagulated	anticoagulated	anticoagul	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)	)	)	)	)	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
OF	NNP	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	O
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	O
EVENTS	NNP	events	event	event	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	B-AdverseReaction
EPIDURAL	NNP	epidural	epidural	epidur	N	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	I-AdverseReaction
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	I-AdverseReaction
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	NN	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
(	(	(	(	(	N	O
A	DT	a	a	a	N	O
)\n\n	NN	)\n\n	)\n\n	)\n\n	N	O
PREMATURE	NNP	premature	premature	prematur	N	O
DISCONTINUATION	NNP	discontinuation	discontinuation	discontinu	N	O
OF	NNP	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
INCREASES	NNP	increases	increase	increas	N	O
THE	NNP	the	the	the	N	O
RISK	NNP	risk	risk	risk	N	O
OF	NNP	of	of	of	N	O
THROMBOTIC	NNP	thrombotic	thrombotic	thrombot	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
EVENTS	NNP	events	event	event	N	O
:	:	:	:	:	N	O
Premature	JJ	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
,	,	,	,	,	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
this	DT	this	this	thi	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
risk	NN	risk	risk	risk	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
if	IN	if	if	if	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
,	,	,	,	,	N	O
2.6	CD	2.6	2.6	2.6	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
SPINAL	NNP	spinal	spinal	spinal	N	O
EPIDURAL	NNP	epidural	epidural	epidur	N	O
HEMATOMA	NNP	hematoma	hematoma	hematoma	Y	O
:	:	:	:	:	N	O
Epidural	JJ	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematomas	NNS	hematomas	hematoma	hematoma	N	I-AdverseReaction
\n\n	VBP	\n\n	\n\n	\n\n	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
undergoing	JJ	undergoing	undergoing	undergo	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
\n\n	NNS	\n\n	\n\n	\n\n	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
term	NN	term	term	term	N	I-AdverseReaction
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
frequently	RB	frequently	frequently	frequent	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
impairment	NN	impairment	impairment	impair	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
observed	VBN	observed	observed	observ	N	O
,	,	,	,	,	N	O
treat	NN	treat	treat	treat	N	O
urgently	RB	urgently	urgently	urgent	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
risks	NNS	risks	risk	risk	N	O
before	IN	before	before	befor	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
intervention	NN	intervention	intervention	intervent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
\n\n	VBP	\n\n	\n\n	\n\n	N	O
need	VBP	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
anticoagulated	VBN	anticoagulated	anticoagulated	anticoagul	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
:	:	:	:	:	N	O
PRADAXA	NN	pradaxa	pradaxa	pradaxa	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Bioprosthetic	JJ	bioprosthetic	bioprosthetic	bioprosthet	N	O
heart	NN	heart	heart	heart	N	O
valves	NNS	valves	valve	valv	N	O
:	:	:	:	:	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
use	NN	use	use	use	N	O
not	RB	not	not	not	N	O
recommended	VBD	recommended	recommended	recommend	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Increased	VBN	increased	increased	increas	N	O

Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
Events	NNS	events	event	event	N	O
after	IN	after	after	after	N	O
Premature	NNP	premature	premature	prematur	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O

Premature	JJ	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
oral	JJ	oral	oral	oral	N	O
anticoagulant	NN	anticoagulant	anticoagulant	anticoagul	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
adequate	JJ	adequate	adequate	adequ	N	O
alternative	JJ	alternative	alternative	altern	N	O
anticoagulation	NN	anticoagulation	anticoagulation	anticoagul	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
reason	NN	reason	reason	reason	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
coverage	NN	coverage	coverage	coverag	N	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
2.5	CD	2.5	2.5	2.5	N	O
,	,	,	,	,	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Bleeding	VBG	bleeding	bleeding	bleed	Y	O

PRADAXA	NN	pradaxa	pradaxa	pradaxa	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	B-AdverseReaction
and	CC	and	and	and	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
significant	JJ	significant	significant	signific	N	B-Severity
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
,	,	,	,	,	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
.	.	.	.	.	N	O

Promptly	RB	promptly	promptly	promptli	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
any	DT	any	any	ani	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
loss	NN	loss	loss	loss	N	O
(	(	(	(	(	N	O
e	JJ	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
drop	NN	drop	drop	drop	N	O
in	IN	in	in	in	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	O
or	CC	or	or	or	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
pathological	JJ	pathological	pathological	patholog	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
include	VBP	include	include	includ	N	O
the	DT	the	the	the	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
increase	VBP	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
platelet	NN	platelet	platelet	platelet	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
heparin	NN	heparin	heparin	heparin	N	O
,	,	,	,	,	N	O
fibrinolytic	JJ	fibrinolytic	fibrinolytic	fibrinolyt	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
chronic	JJ	chronic	chronic	chronic	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
's	POS	's	's	's	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
activity	NN	activity	activity	activ	N	O
and	CC	and	and	and	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
life	NN	life	life	life	N	O
are	VBP	are	are	are	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Reversal	NNP	reversal	reversal	revers	N	O
of	IN	of	of	of	N	O
Anticoagulant	NNP	anticoagulant	anticoagulant	anticoagul	N	O
Effect	NNP	effect	effect	effect	N	O
:	:	:	:	:	N	O
A	DT	a	a	a	N	O
specific	JJ	specific	specific	specif	N	O
reversal	NN	reversal	reversal	revers	N	O
agent	NN	agent	agent	agent	N	O
for	IN	for	for	for	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

Hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
can	MD	can	can	can	N	O
remove	VB	remove	remove	remov	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
experience	NN	experience	experience	experi	N	O
supporting	VBG	supporting	supporting	support	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
hemodialysis	NN	hemodialysis	hemodialysis	hemodialysi	Y	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
is	VBZ	is	is	is	N	O
limited	JJ	limited	limited	limit	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Overdosage	NNP	overdosage	overdosage	overdosag	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Activated	NNP	activated	activated	activ	N	O
prothrombin	NN	prothrombin	prothrombin	prothrombin	Y	O
complex	NN	complex	complex	complex	N	O
concentrates	NNS	concentrates	concentrate	concentr	N	O
(	(	(	(	(	N	O
aPCCs	NN	apccs	apccs	apcc	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
FEIBA	NNP	feiba	feiba	feiba	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
recombinant	JJ	recombinant	recombinant	recombin	N	O
Factor	NNP	factor	factor	factor	N	O
VIIa	NNP	viia	viia	viia	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
concentrates	NNS	concentrates	concentrate	concentr	N	O
of	IN	of	of	of	N	O
coagulation	NN	coagulation	coagulation	coagul	N	O
factors	NNS	factors	factor	factor	N	O
II	NNP	ii	ii	ii	N	O
,	,	,	,	,	N	O
IX	NNP	ix	ix	ix	N	O
or	CC	or	or	or	N	O
X	NNP	x	x	x	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
but	CC	but	but	but	N	O
their	PRP$	their	their	their	N	O
use	NN	use	use	use	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Protamine	NNP	protamine	protamine	protamin	N	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
vitamin	NN	vitamin	vitamin	vitamin	N	O
K	NNP	k	k	k	Y	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
affect	VB	affect	affect	affect	N	O
the	DT	the	the	the	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
activity	NN	activity	activity	activ	N	O
of	IN	of	of	of	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
platelet	NN	platelet	platelet	platelet	N	O
concentrates	NNS	concentrates	concentrate	concentr	N	O
in	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
where	WRB	where	where	where	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
is	VBZ	is	is	is	N	O
present	JJ	present	present	present	N	O
or	CC	or	or	or	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
acting	VBG	acting	acting	act	N	O
antiplatelet	NN	antiplatelet	antiplatelet	antiplatelet	N	O
drugs	NNS	drugs	drug	drug	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
used	VBN	used	used	use	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Spinal	JJ	spinal	spinal	spinal	N	O
Epidural	NNP	epidural	epidural	epidur	N	O
Anesthesia	NNP	anesthesia	anesthesia	anesthesia	Y	O
or	CC	or	or	or	N	O
Puncture	NN	puncture	puncture	punctur	N	O

When	WRB	when	when	when	N	O
neuraxial	JJ	neuraxial	neuraxial	neuraxi	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
(	(	(	(	(	N	O
spinal	JJ	spinal	spinal	spinal	N	O
epidural	JJ	epidural	epidural	epidur	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
is	VBZ	is	is	is	N	O
employed	VBN	employed	employed	employ	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	B-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
an	DT	an	an	an	N	O
epidural	JJ	epidural	epidural	epidur	N	B-AdverseReaction
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	B-AdverseReaction
hematoma	NN	hematoma	hematoma	hematoma	Y	I-AdverseReaction
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
or	CC	or	or	or	N	O
permanent	JJ	permanent	permanent	perman	N	B-AdverseReaction
paralysis	NN	paralysis	paralysis	paralysi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
]	NNP	]	]	]	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
bleeding	VBG	bleeding	bleeding	bleed	Y	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
and	CC	and	and	and	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
analgesia	NN	analgesia	analgesia	analgesia	Y	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
puncture	NN	puncture	puncture	punctur	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
profile	NN	profile	profile	profil	N	O
of	IN	of	of	of	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Placement	NN	placement	placement	placement	N	O
or	CC	or	or	or	N	O
removal	NN	removal	removal	remov	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
epidural	JJ	epidural	epidural	epidur	N	O
catheter	NN	catheter	catheter	cathet	N	O
or	CC	or	or	or	N	O
lumbar	NN	lumbar	lumbar	lumbar	N	O
puncture	NN	puncture	puncture	punctur	N	O
is	VBZ	is	is	is	N	O
best	RBS	best	best	best	N	O
performed	VBN	performed	performed	perform	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
is	VBZ	is	is	is	N	O
low	JJ	low	low	low	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
exact	JJ	exact	exact	exact	N	O
timing	NN	timing	timing	time	N	O
to	TO	to	to	to	N	O
reach	VB	reach	reach	reach	N	O
a	DT	a	a	a	N	O
sufficiently	RB	sufficiently	sufficiently	suffici	N	O
low	JJ	low	low	low	N	O
anticoagulant	JJ	anticoagulant	anticoagulant	anticoagul	N	O
effect	NN	effect	effect	effect	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
the	DT	the	the	the	N	O
physician	JJ	physician	physician	physician	N	O
decide	NN	decide	decide	decid	N	O
to	TO	to	to	to	N	O
administer	VB	administer	administer	administ	N	O
anticoagulation	NN	anticoagulation	anticoagulation	anticoagul	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
context	NN	context	context	context	N	O
of	IN	of	of	of	N	O
epidural	JJ	epidural	epidural	epidur	N	O
or	CC	or	or	or	N	O
spinal	JJ	spinal	spinal	spinal	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
analgesia	NN	analgesia	analgesia	analgesia	Y	O
or	CC	or	or	or	N	O
lumbar	NN	lumbar	lumbar	lumbar	N	O
puncture	NN	puncture	puncture	punctur	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
frequently	RB	frequently	frequently	frequent	N	O
to	TO	to	to	to	N	O
detect	VB	detect	detect	detect	N	O
any	DT	any	any	ani	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
midline	NN	midline	midline	midlin	N	O
back	RB	back	back	back	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
sensory	NN	sensory	sensory	sensori	N	O
and	CC	and	and	and	N	O
motor	NN	motor	motor	motor	N	O
deficits	NNS	deficits	deficit	deficit	N	O
(	(	(	(	(	N	O
numbness	NN	numbness	numbness	numb	Y	O
,	,	,	,	,	N	O
tingling	VBG	tingling	tingling	tingl	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
weakness	NN	weakness	weakness	weak	Y	O
in	IN	in	in	in	N	O
lower	JJR	lower	lower	lower	N	O
limbs	NN	limbs	limb	limb	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bowel	NN	bowel	bowel	bowel	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
bladder	JJR	bladder	bladder	bladder	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
.	.	.	.	.	N	O

Instruct	NN	instruct	instruct	instruct	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
immediately	RB	immediately	immediately	immedi	N	O
report	VB	report	report	report	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
experience	VBP	experience	experience	experi	N	O
any	DT	any	any	ani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
above	JJ	above	above	abov	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
spinal	JJ	spinal	spinal	spinal	N	O
hematoma	NN	hematoma	hematoma	hematoma	Y	O
are	VBP	are	are	are	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
initiate	JJ	initiate	initiate	initi	N	O
urgent	JJ	urgent	urgent	urgent	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
including	VBG	including	including	includ	N	O
consideration	NN	consideration	consideration	consider	N	O
for	IN	for	for	for	N	O
spinal	JJ	spinal	spinal	spinal	N	O
cord	NN	cord	cord	cord	N	O
decompression	NN	decompression	decompression	decompress	N	O
even	RB	even	even	even	N	O
though	IN	though	though	though	N	O
such	JJ	such	such	such	N	O
treatment	NN	treatment	treatment	treatment	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
prevent	VB	prevent	prevent	prevent	N	O
or	CC	or	or	or	N	O
reverse	VB	reverse	reverse	revers	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
sequelae	NN	sequelae	sequela	sequela	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	O
and	CC	and	and	and	N	O
Bleeding	NNP	bleeding	bleeding	bleed	Y	O
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Prosthetic	NNP	prosthetic	prosthetic	prosthet	N	B-AdverseReaction
Heart	NNP	heart	heart	heart	N	I-AdverseReaction
Valves	VBZ	valves	valve	valv	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bileaflet	JJ	bileaflet	bileaflet	bileaflet	N	O
mechanical	JJ	mechanical	mechanical	mechan	N	O
prosthetic	JJ	prosthetic	prosthetic	prosthet	N	O
heart	NN	heart	heart	heart	N	O
valves	NNS	valves	valve	valv	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
ALIGN	NNP	align	align	align	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bileaflet	JJ	bileaflet	bileaflet	bileaflet	N	O
mechanical	JJ	mechanical	mechanical	mechan	N	O
prosthetic	JJ	prosthetic	prosthetic	prosthet	N	O
heart	NN	heart	heart	heart	N	O
valves	NNS	valves	valve	valv	N	O
(	(	(	(	(	N	O
recently	RB	recently	recently	recent	N	O
implanted	VBN	implanted	implanted	implant	N	O
or	CC	or	or	or	N	O
implanted	VBN	implanted	implanted	implant	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
enrollment	NN	enrollment	enrollment	enrol	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
adjusted	JJ	adjusted	adjusted	adjust	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
or	CC	or	or	or	N	O
150	CD	150	150	150	N	O
,	,	,	,	,	N	O
220	CD	220	220	220	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
twice	RB	twice	twice	twice	N	O
a	DT	a	a	a	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

RE	NNP	re	re	re	N	O
-	:	-	-	-	N	O
ALIGN	NNP	align	align	align	N	O
was	VBD	was	wa	wa	N	O
terminated	VBN	terminated	terminated	termin	N	O
early	RB	early	early	earli	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
significantly	RB	significantly	significantly	significantli	N	O
more	RBR	more	more	more	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
valve	JJ	valve	valve	valv	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	I-AdverseReaction
,	,	,	,	,	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
excess	NN	excess	excess	excess	N	O
of	IN	of	of	of	N	O
major	JJ	major	major	major	N	B-Severity
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
(	(	(	(	(	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
post	VBN	post	post	post	N	O
-	:	-	-	-	N	O
operative	JJ	operative	operative	oper	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
effusions	NNS	effusions	effusion	effus	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
intervention	NN	intervention	intervention	intervent	N	O
for	IN	for	for	for	N	O
hemodynamic	JJ	hemodynamic	hemodynamic	hemodynam	N	O
compromise	NN	compromise	compromise	compromis	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
warfarin	NN	warfarin	warfarin	warfarin	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	B-AdverseReaction
and	CC	and	and	and	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
seen	VBN	seen	seen	seen	N	O
both	DT	both	both	both	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
initiated	VBN	initiated	initiated	initi	N	O
on	IN	on	on	on	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
operatively	RB	operatively	operatively	oper	N	O
within	IN	within	within	within	N	O
three	CD	three	three	three	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
mechanical	JJ	mechanical	mechanical	mechan	N	O
bileaflet	NN	bileaflet	bileaflet	bileaflet	N	O
valve	NN	valve	valve	valv	N	O
implantation	NN	implantation	implantation	implant	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
valves	NNS	valves	valve	valv	N	O
had	VBD	had	had	had	N	O
been	VBN	been	been	been	N	O
implanted	VBN	implanted	implanted	implant	N	O
more	RBR	more	more	more	N	O
than	IN	than	than	than	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
enrollment	NN	enrollment	enrollment	enrol	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mechanical	JJ	mechanical	mechanical	mechan	N	O
prosthetic	JJ	prosthetic	prosthetic	prosthet	N	O
valves	NNS	valves	valve	valv	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
of	IN	of	of	of	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
valvular	JJ	valvular	valvular	valvular	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
bioprosthetic	JJ	bioprosthetic	bioprosthetic	bioprosthet	N	O
heart	NN	heart	heart	heart	N	O
valve	NN	valve	valve	valv	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Effect	NNP	effect	effect	effect	N	O
of	IN	of	of	of	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
Inducers	NNS	inducers	inducer	induc	N	O
and	CC	and	and	and	N	O
Inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
on	IN	on	on	on	N	O
Dabigatran	NNP	dabigatran	dabigatran	dabigatran	N	O
Exposure	NN	exposure	exposure	exposur	N	O

The	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
with	IN	with	with	with	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
inducers	NNS	inducers	inducer	induc	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
rifampin	NN	rifampin	rifampin	rifampin	N	O
)	)	)	)	)	N	O
reduces	VBZ	reduces	reduces	reduc	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
dabigatran	VB	dabigatran	dabigatran	dabigatran	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
generally	RB	generally	generally	gener	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
and	CC	and	and	and	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
are	VBP	are	are	are	N	O
the	DT	the	the	the	N	O
major	JJ	major	major	major	N	O
independent	JJ	independent	independent	independ	N	O
factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
result	VBP	result	result	result	N	O
in	IN	in	in	in	N	O
increased	JJ	increased	increased	increas	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
dabigatran	VB	dabigatran	dabigatran	dabigatran	N	O
[	NNP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Concomitant	NNP	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
is	VBZ	is	is	is	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
increased	JJ	increased	increased	increas	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
dabigatran	NN	dabigatran	dabigatran	dabigatran	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
seen	VBN	seen	seen	seen	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
factor	NN	factor	factor	factor	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
and	CC	and	and	and	N	O
Systemic	NNP	systemic	systemic	system	N	O
Embolism	NNP	embolism	embolism	embol	Y	O
in	IN	in	in	in	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
valvular	JJ	valvular	valvular	valvular	N	O
Atrial	NNP	atrial	atrial	atrial	N	O
Fibrillation	NN	fibrillation	fibrillation	fibril	Y	O

Reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
to	TO	to	to	to	N	O
75	CD	75	75	75	N	O
mg	NNS	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
when	WRB	when	when	when	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
or	CC	or	or	or	N	O
systemic	JJ	systemic	systemic	system	N	O
ketoconazole	NN	ketoconazole	ketoconazole	ketoconazol	N	O
is	VBZ	is	is	is	N	O
coadministered	VBN	coadministered	coadministered	coadminist	N	O
with	IN	with	with	with	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
CrCl	NNP	crcl	crcl	crcl	N	O
30	CD	30	30	30	N	O
-	:	-	-	-	N	O
50	CD	50	50	50	N	O
mL	NNS	ml	ml	ml	N	O
min	NN	min	min	min	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
and	CC	and	and	and	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
CrCl	NNP	crcl	crcl	crcl	N	O
15	CD	15	15	15	N	O
-	:	-	-	-	N	O
30	CD	30	30	30	N	O
mL	NNS	ml	ml	ml	N	O
min	NN	min	min	min	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
Reduction	NNP	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Recurrence	NNP	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
Deep	NNP	deep	deep	deep	N	O
Venous	NNP	venous	venous	venou	N	O
Thrombosis	NNP	thrombosis	thrombosis	thrombosi	Y	O
and	CC	and	and	and	N	O
Pulmonary	NNP	pulmonary	pulmonary	pulmonari	N	O
Embolism	NNP	embolism	embolism	embol	Y	O

Avoid	NNP	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PRADAXA	NNP	pradaxa	pradaxa	pradaxa	N	O
and	CC	and	and	and	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
P	NNP	p	p	p	Y	O
-	:	-	-	-	N	O
gp	NN	gp	gp	gp	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CrCl	NNP	crcl	crcl	crcl	N	O
50	CD	50	50	50	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

